Pomerantz LLP is investigating argenx SE for potential securities fraud following the discontinuation of a Phase 3 clinical trial for efgartigimod in Sjögren's disease due to futility. This investigation suggests potential legal repercussions for the company and its officers, stemming from the significant stock price drop after the trial's failure.
Pomerantz LLP has initiated an investigation into argenx SE for potential securities fraud. This stems from the company's announcement on October 8, 2026, that it would discontinue its Phase 3 UNITY study of efgartigimod for Sjögren's disease due to futility, based on an independent committee's recommendation. The news led to an 11.83% drop in argenx's stock price, indicating significant investor concern. This investigation could lead to class-action lawsuits, potentially resulting in financial penalties and reputational damage for argenx SE and its leadership. For traders, this represents a short-term negative catalyst due to legal uncertainty and the failure of a key pipeline asset, with long-term implications depending on the outcome of the investigation and the company's other drug development efforts.